We started with HMA to prime the SALL4 negative lung cancer cells to become SALL4 positive, therefore, to induce a SALL4-mediated vulnerability in these cells, and then sensitized these cells to the following Entinostat treatment. Here, SALL4 is linked to lung cancer.